Clinical Report: Differentiating Prostate Cancer and Chronic Prostatitis Using T2 Mapping

Overview

This study evaluated the utility of quantitative T2 mapping in distinguishing prostate cancer (PCa) from chronic prostatitis in patients undergoing mpMRI and robot-assisted biopsy. T2 relaxation times were significantly lower in PCa lesions compared to chronic prostatitis and normal tissue, demonstrating diagnostic potential comparable to ADC values.

Background

Prostate cancer is the most common non-cutaneous cancer in men, with mpMRI currently the best imaging modality for detection and localization. Differentiating PCa from chronic prostatitis is challenging due to overlapping imaging features on standard mpMRI sequences, especially in PI-RADS 3 lesions. Quantitative T2 mapping offers absolute T2 relaxation times independent of signal intensity variations, potentially improving lesion characterization beyond conventional T2-weighted imaging and ADC maps.

Data Highlights

Key Findings

• Quantitative T2 values were significantly lower in prostate cancer lesions compared to chronic prostatitis and normal peripheral zone tissue.
• T2 mapping provided absolute quantitative measurements independent of coil-related signal variations, enhancing lesion characterization.
• The diagnostic accuracy of T2 values in differentiating PCa from chronic prostatitis was comparable to that of ADC values derived from diffusion-weighted imaging.
• Histopathology from robot-assisted mpMRI-TRUS fusion biopsy served as the reference standard, ensuring precise lesion correlation.
• PI-RADS v2.1 scoring was used to select lesions with suspicion for PCa, with chronic prostatitis frequently found in PI-RADS 3 lesions.

Clinical Implications

Incorporating quantitative T2 mapping into routine mpMRI protocols may improve differentiation between prostate cancer and chronic prostatitis, particularly in ambiguous PI-RADS 3 lesions. This could reduce unnecessary biopsies and improve diagnostic confidence. T2 mapping offers a reproducible, quantitative biomarker complementary to ADC values for prostate lesion assessment.

Conclusion

Quantitative T2 mapping is a promising tool for distinguishing prostate cancer from chronic prostatitis, providing diagnostic accuracy comparable to ADC measurements. Its integration into clinical mpMRI protocols may enhance lesion characterization and patient management.

References

1. European Society of Urogenital Radiology Guidelines
2. PI-RADS v2.1 Standardization
3. Robot-assisted mpMRI-TRUS Fusion Biopsy Technique